Recent publications

• Ferric Derisomaltose Compared to Iron Sucrose in Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials March 14, 2026
  Background/Objectives: There are conflicting results on the effects of ferric derisomaltose (FDM) vs. iron sucrose (IS) for treatment of iron deficiency anemia (IDA). We systematically assessed the efficacy and safety of these treatments. Methods: We searched Ovid MEDLINE, Web of Science, Pubmed, and Cochrane Central for randomized controlled trials (RCTs) comparing the efficacy and/or safety […]
  Lokman H Tanriverdi
• Utilization and clinical characteristics of patients with type 2 diabetes and chronic kidney disease prescribed finerenone in the United States March 11, 2026
  CONCLUSIONS: Finerenone was primarily prescribed as a pillar of therapy that is used in combination with complementary medications in patients with T2D and CKD, aligning with clinical guidelines and regulatory labeling.
  Csaba P Kovesdy
• Bury my axe in wounded knee: A case of native knee septic arthritis caused by multidrug resistant <em>Lomentospora</em> <em>prolificans</em> March 9, 2026
  A 39-year-old male presenting with swelling and pain in the left knee after traumatic injury was diagnosed with rapidly progressive septic arthritis of the knee due to pan-resistant Lomentospora prolificans. While L. prolificans is an environmental mold, it infrequently causes infection in immunocompetent patients. These hosts most commonly suffer soft tissue or osteoarticular infections following […]
  Weston Carpenter
• Using the ACCP Toolkit to Evolve the PharmD Curriculum March 1, 2026
  CONCLUSION: Using the ACCP Toolkit in the curricular assessment process was effective in identifying areas of curricular overload and informing areas for improvement in a subsequent curricular revision, leading to adjustment of credits and time spent on pharmacotherapy topics within courses.
  Jennifer Luciano
• Short-Term Care Burden After Left Ventricular Assist Device Implantation and Heart Transplant in the United States February 24, 2026
  CONCLUSIONS: Both LVAD and HT had comparable burdens on resources and short-term rehospitalization risk.
  Balaphanidhar Mogga
• Efficacy and harms of polypills for cardiovascular disease prevention: A systematic review and meta-analysis of randomized controlled trials February 20, 2026
  CONCLUSIONS: In primary and secondary prevention settings, polypills had moderate reductions of CV outcomes, small effects on CV risk factors, and small increases of AEs.
  Brian M Portela
• Risk scoring for the primary prevention of cardiovascular disease February 17, 2026
  This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of evaluating and providing cardiovascular disease (CVD) risk scores in adults without prevalent CVD on cardiovascular outcomes, risk factor levels, preventive medication prescribing, and health behaviours.
  Adrian V Hernandez
• The 2025 Invitational Summit on Medicaid Payment for Pharmacist Patient Care Services: Meeting proceedings February 15, 2026
  No abstract
  Marie A Smith
• Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown February 14, 2026
  CONCLUSION AND RELEVANCE: We found little justification for adding nutrients or docusate sodium to combination subcutaneous semaglutide or tirzepatide products. There is a rationale for adding ondansetron, but evidence for subcutaneous administration is lacking. There is a rationale for fashioning sublingual or ODT formulations, but whether these formulations offer advantages over innovator oral tablets has […]
  Jordyn Belcourt
• Why the Birth Dose Matters for Hepatitis B Vaccination February 12, 2026
  No abstract
  Jennifer E Girotto
• Nonswallowed Kratom-Derived Products: Unlawful Dietary Supplements That Endanger Public Health January 26, 2026
  The Dietary Supplement Health and Education Act of 1994 specified that dietary supplements must be swallowed. In this study, we investigated whether kratom-derived products are being sold to consumers in nonswallowed formulations. Kratom is the fresh or dried leaf powder of the Mitragyna speciosa tree. We identified 49 kratom-derived products being sold in the form […]
  C Michael White
• Harnessing the Power of Artificial Intelligence to Enhance Drug Therapy Research January 14, 2026
  No abstract
  William L Baker
• Concurrent Administration of Triazoles with Chemotherapeutic and/or Immunosuppressant Agents Known to Have Moderate-to-Severe Drug-Drug Interactions in Patients with Hematologic Malignancies Hospitalized for Invasive Aspergillosis January 13, 2026
  CONCLUSIONS: Concurrent administration of triazole with potential PK interactions with CT or IS agents occurred in most HM patients admitted for IA. Choosing alternative antifungals, therapeutic drug monitoring of triazoles or selective ISs, and dosage adjustment of CT/IS agents may mitigate the risk of adverse DDIs. New antifungal agents without serious DDIs with CT and/or […]
  Thomas J Walsh
• Predicting cardiovascular outcomes in elderly patients with acute coronary syndrome: a nomogram approach January 9, 2026
  CONCLUSION: A nomogram successfully predicts MACE risk in older STEMI patients using laboratory, clinical, and procedural parameters. This algorithm may identify vulnerable high-risk patients for more aggressive preventative interventions.
  Hamidreza Soleimani
• PCSK9 and ANGPTL3 Inhibitors in Homozygous Familial Hypercholesterolemia: A Meta-analysis of Randomized Clinical Trials January 7, 2026
  CONCLUSIONS: PCSK9 inhibitors have lower efficacy in reducing lipid levels in HoFH compared with ANGPTL3 inhibitors, with the greatest difference seen in patients with the negative LDLR genotype. Further studies are needed to clarify efficacy across LDLR functional variants.
  Ibadete Bytyçi
• Transdermal "Natural GLP-1" Dietary Supplements Violate Law and Place Patients at Risk January 2, 2026
  Consumers precluded from obtaining semaglutide or tirzepatide by clinicians or insurers are turning to natural "GLP-1" transdermal patches. The Dietary Supplement Health and Education Act specifies dietary supplement products must be swallowed, so all these products are illegal. We identified 24 transdermal patch dietary supplement products and 1 transdermal gel product with an average of […]
  C Michael White
• Co-administration of triazoles with calcineurin or mammalian target of rapamycin inhibitors in solid organ transplant patients hospitalized with invasive aspergillosis December 19, 2025
  CONCLUSIONS: Voriconazole was used nearly twice as frequently as isavuconazole, despite isavuconazole having more predictable pharmacokinetics and a lower propensity for severe drug-drug interactions versus voriconazole. The still-frequent use of isavuconazole may reflect its lower inhibition of CNIs and mTOR inhibitors. Resulting drug-drug interactions may be serious and dose adjustment and therapeutic drug monitoring are […]
  Barbara Alexander
• Continuing as Partners in Immunization: Building Immunization Confidence Through Communication, Education, and Resources December 19, 2025
  Immunizations are among the most effective public health measures, significantly reducing the prevalence of serious infectious diseases across the population. Their success is so profound that many in the United States have never witnessed the devastating effects of illnesses, such as measles, polio, or diphtheria. Despite this progress, the Centers for Disease Control and Prevention […]
  Jennifer E Girotto
• Engineering Nanoparticles to Modulate Extracellular Matrix and Immune Components of the Tumor Microenvironment in Cancer Immunotherapy December 11, 2025
  Cancer immunotherapy has emerged as a transformative strategy for treating malignancies by harnessing the body's immune system. However, its clinical efficacy is often limited by the complex and immunosuppressive nature of the tumor microenvironment (TME), which poses substantial barriers to therapeutic success. The TME comprises a variety of components, including immune cells, cancer-associated fibroblasts, abnormal […]
  Bao-Toan Dang
• Temporal Changes in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use in Patients with Chronic Kidney Disease and Type 2 Diabetes, 2012-2023: A US Cohort Study December 9, 2025
  CONCLUSIONS: These findings inform and contextualize future studies assessing cardiorenal outcomes for these and additional treatments, including finerenone, for individuals with CKD and type 2 diabetes.
  Catherine B Johannes